Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic spontaneous urticaria
Biotech
Celldex monoclonal antibody rebounds with pair of phase 3 wins
The trials met both primary and secondary endpoints, giving Celldex’s barzolvolimab a chance at redemption after its recent phase 2 flop.
Marissa Russo
Sep 22, 2026 10:30am
Cue chalks up phase 2 hives win for Xolair challenger
Sep 21, 2026 4:50am
Processa acquires Vidya for potential rival to Rhapsido
Jul 29, 2026 10:10am
Evommune’s phase 2b flops, ending challenge to Novartis in hives
Jun 29, 2026 10:00am
Inflammation biotech Evommune eyes IPO to fund dermatitis trials
Oct 10, 2025 6:35am
Jasper halves workforce after dud drug surprise, narrows R&D focus
Jul 9, 2025 9:07am
